All Stories

  1. Khosrow Kashfi Bio

    Article • Critical Reviews™ in Oncogenesis, January 2023, Begell House

    Dr Khosrow Kashfi

  2. Preface

    Article • Critical Reviews™ in Oncogenesis, January 2023, Begell House

    Dr Khosrow Kashfi

  3. Preface

    Article • November 2022, Bentham Science Publishers

    Dr Khosrow Kashfi

  4. Carbon monoxide in cell signaling and potential therapeutics

    Article • Biochemical Pharmacology, October 2022, Elsevier

    Dr Khosrow Kashfi

  5. Acidified nitrite improves wound healing in type 2 diabetic rats: Role of oxidative stress and inflammation

    Article • Nitric Oxide, October 2020, Elsevier

    Dr Khosrow Kashfi

  6. Impaired cardiovascular function in male rats with hypo- and hyperthyroidism: Involvement of imbalanced nitric oxide synthase levels

    Article • Endocrine Metabolic & Immune Disorders - Drug Targets, May 2020, Bentham Science Publishers

    Dr Khosrow Kashfi, Dr Asghar Ghasemi

  7. The Principles of Biomedical Scientific Writing: Citation

    Article • International Journal of Endocrinology and Metabolism, April 2020, Kowsar Medical Institute

    Dr Khosrow Kashfi

  8. Nitric oxide in cancer and beyond

    Article • Biochemical Pharmacology, April 2020, Elsevier

    Dr Khosrow Kashfi

  9. Chemical stimulation of the lateral hypothalamus induces antiallodynic and anti-thermal hyperalgesic effects in animal model of neuropathic pain: Involvement of orexin receptors in the spinal cord

    Article • Brain Research, April 2020, Elsevier

    Dr Khosrow Kashfi

  10. The evolving landscape for cellular nitric oxide and hydrogen sulfide delivery systems: A new era of customized medications

    Article • Biochemical Pharmacology, March 2020, Elsevier

    Dr Khosrow Kashfi

  11. Tumor associated macrophages and ‘NO’

    Article • Biochemical Pharmacology, March 2020, Elsevier

    Dr Khosrow Kashfi

  12. Dose-Dependent Effects of Long-Term Administration of Hydrogen Sulfide on Myocardial Ischemia–Reperfusion Injury in Male Wistar Rats: Modulation of RKIP, NF-κB, and Oxidative Stress

    Article • International Journal of Molecular Sciences, February 2020, MDPI AG

    Dr Khosrow Kashfi

  13. NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS

    Article • Biochemical Pharmacology, February 2020, Elsevier

    Dr Khosrow Kashfi

  14. The Principles of Biomedical Scientific Writing: Abstract and Keywords

    Article • International Journal of Endocrinology and Metabolism, January 2020, Kowsar Medical Institute

    Dr Khosrow Kashfi

  15. Exploring the Potential of Nitric Oxide and Hydrogen Sulfide (NOSH)-Releasing Synthetic Compounds as Novel Priming Agents against Drought Stress in Medicago sativa Plants

    Article • Biomolecules, January 2020, MDPI AG

    Dr Khosrow Kashfi

  16. Regulation of carbohydrate metabolism by nitric oxide and hydrogen sulfide: Implications in diabetes

    Article • Biochemical Pharmacology, January 2020, Elsevier

    Dr Khosrow Kashfi

  17. Hydrogen sulfide potentiates the favorable metabolic effects of inorganic nitrite in type 2 diabetic rats

    Article • Nitric Oxide, November 2019, Elsevier

    Dr Khosrow Kashfi

  18. The Principles of Biomedical Scientific Writing: Title

    Article • International Journal of Endocrinology and Metabolism, October 2019, Kowsar Medical Institute

    Dr Khosrow Kashfi

  19. Data Extraction from Graphs Using Adobe Photoshop: Applications for Meta-Analyses

    Article • International Journal of Endocrinology and Metabolism, October 2019, Kowsar Medical Institute

    Dr Khosrow Kashfi

  20. Altered gene expression of hydrogen sulfide‐producing enzymes in the liver and muscles tissues of hyperthyroid rats

    Article • Journal of Cellular Physiology, March 2019, Wiley

    Dr Khosrow Kashfi

  21. Effects of Hydrogen Sulfide on Carbohydrate Metabolism in Obese Type 2 Diabetic Rats

    Article • Molecules, January 2019, MDPI AG

    Dr Khosrow Kashfi

  22. Obesity, Type-2 Diabetes and Cancer: Mechanistic Insights

    Article • Critical Reviews™ in Oncogenesis, January 2019, Begell House

    Dr Khosrow Kashfi

  23. Type 2 Diabetes and Cancer: The Nitric Oxide Connection

    Article • Critical Reviews™ in Oncogenesis, January 2019, Begell House

    Dr Khosrow Kashfi

  24. Development of new generation of vaccines for Brucella abortus

    Article • Heliyon, December 2018, Elsevier

    Dr Khosrow Kashfi

  25. Effects of long-term oral nitrate administration on adiposity in normal adult female rats

    Article • Life Sciences, October 2018, Elsevier

    Dr Khosrow Kashfi

  26. The role of hydrogen sulfide in health and disease

    Article • Biochemical Pharmacology, March 2018, Elsevier

    Dr Khosrow Kashfi

  27. The dichotomous role of H2S in cancer cell biology? Déjà vu all over again

    Article • Biochemical Pharmacology, March 2018, Elsevier

    Dr Khosrow Kashfi

  28. Regulation of vascular tone homeostasis by NO and H2S: Implications in hypertension

    Article • Biochemical Pharmacology, March 2018, Elsevier

    Dr Khosrow Kashfi

  29. A practical guide for induction of type-2 diabetes in rat: Incorporating a high-fat diet and streptozotocin

    Article • Biomedicine & Pharmacotherapy, November 2017, Elsevier

    Dr Khosrow Kashfi

  30. NO-H 2 S-Releasing Chimeras as a Multifaceted Approach to Cancer Therapy

    Article • January 2017, Elsevier

    Dr Khosrow Kashfi

  31. Nitric Oxide Donors and Therapeutic Applications in Cancer

    Article • January 2017, Elsevier

    Dr Khosrow Kashfi

  32. Gastrointestinal safety, chemotherapeutic potential, and classic pharmacological profile of NOSH ‐naproxen ( AVT ‐219) a dual NO‐ and H 2 S‐releasing hybrid

    Article • Pharmacology Research & Perspectives, March 2016, Wiley

    Dr Khosrow Kashfi

  33. The dual role of iNOS in cancer

    Article • Redox Biology, December 2015, Elsevier

    Dr Khosrow Kashfi

  34. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications

    Article • Biochemical Pharmacology, December 2015, Elsevier

    Dr Khosrow Kashfi

  35. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling

    Article • Redox Biology, December 2015, Elsevier

    Dr Khosrow Kashfi

  36. Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid

    Article • Bioorganic & Medicinal Chemistry Letters, October 2015, Elsevier

    Dr Khosrow Kashfi

  37. HS-Naproxen

    Article • Drug Design Development and Therapy, August 2015, Dove Medical Press

    Dr Khosrow Kashfi, Dr Ravinder Kodela

  38. Utility Of Nitric Oxide And Hydrogen Sulfide-Releasing Chimeras As Anticancer Agents

    Article • Redox Biology, August 2015, Elsevier

    Dr Khosrow Kashfi

  39. NOSH-Aspirin Inhibits Colon Cancer Cell Growth: Effects Of Positional Isomerism

    Article • Redox Biology, August 2015, Elsevier

    Dr Khosrow Kashfi

  40. NOSH-aspirin (NBS-1120), a dual nitric oxide and hydrogen sulfide-releasing hybrid, reduces inflammatory pain

    Article • Pharmacology Research & Perspectives, May 2015, Wiley

    Dr Khosrow Kashfi

  41. P77

    Article • Nitric Oxide, May 2014, Elsevier

    Dr Khosrow Kashfi

  42. 287 Targeting NF-κB, FoxM1, and p53 in Pancreatic Cancer With NOSH-Aspirin

    Article • Gastroenterology, May 2014, Elsevier

    Dr Khosrow Kashfi

  43. Anti-Cancer Activity of New Designer Hydrogen Sulfide-Donating Hybrids

    Article • Antioxidants & Redox Signaling, February 2014, Mary Ann Liebert Inc

    Dr Khosrow Kashfi

  44. Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates β-catenin expression

    Article • Leukemia Research, October 2013, Elsevier

    Dr Khosrow Kashfi

  45. P09 Therapeutic potential of NOSH-aspirin, a dual nitric oxide- and hydrogen sulfide-donating hybrid in colon cancer

    Article • Nitric Oxide, September 2013, Elsevier

    Dr Khosrow Kashfi

  46. NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: A new candidate for treatment of neurodegenerative disorders

    Article • Glia, August 2013, Wiley

    Dr Khosrow Kashfi

  47. Flurbiprofen benzyl nitrate (NBS-242) inhibits the growth of A-431 human epidermoid carcinoma cells and targets ß-catenin

    Article • Drug Design Development and Therapy, May 2013, Taylor & Francis

    Dr Khosrow Kashfi

  48. Abstract 4793: NOSH-aspirin inhibits breast cancer cell growth: an effect modulated through reactive oxygen species and independent of the ER status.

    Article • April 2013, American Association for Cancer Research (AACR)

    Dr Khosrow Kashfi

  49. Dysfunctional cell signaling dynamics in oncology: Diagnostic, prognostic and treatment opportunities

    Article • Biochemical Pharmacology, March 2013, Elsevier

    Dr Khosrow Kashfi

  50. Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras

    Article • Biochemical Pharmacology, March 2013, Elsevier

    Dr Khosrow Kashfi

  51. Positional Isomers of Aspirin Are Equally Potent in Inhibiting Colon Cancer Cell Growth: Differences in Mode of Cyclooxygenase Inhibition

    Article • Journal of Pharmacology and Experimental Therapeutics, January 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Khosrow Kashfi

  52. Synthesis and biological activity of NOSH-naproxen (AVT-219) and NOSH-sulindac (AVT-18A) as potent anti-inflammatory agents with chemotherapeutic potential

    Article • MedChemComm, January 2013, Royal Society of Chemistry

    Dr Khosrow Kashfi

  53. Abstract B34: NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid for treatment of cancer

    Article • Cancer Prevention Research, November 2012, American Association for Cancer Research (AACR)

    Dr Khosrow Kashfi

  54. Abstract 3898: NOSH-aspirin: A novel nitric oxide- and hydrogen sulfide-releasing hybrid for treatment of colon cancer

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr Khosrow Kashfi

  55. Abstract 3899: NOSH compounds: Nitric oxide- and hydrogen sulfide-releasing hybrids, a new class of anti-inflammatory pharmaceuticals

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr Khosrow Kashfi

  56. Abstract 3891: NOSH-aspirin, a novel nitric oxide- and hydrogen sulfide-releasing hybrid, is a potent inhibitor of colon cancer cell growth

    Article • April 2012, American Association for Cancer Research (AACR)

    Dr Khosrow Kashfi

  57. NOSH-Aspirin: A Novel Nitric Oxide–Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals

    Article • ACS Medicinal Chemistry Letters, March 2012, American Chemical Society (ACS)

    Dr Khosrow Kashfi

  58. Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo

    Article • Biochemical Pharmacology, March 2012, Elsevier

    Dr Khosrow Kashfi

  59. NOSH–aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model

    Article • Biochemical and Biophysical Research Communications, March 2012, Elsevier

    Dr Khosrow Kashfi

  60. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo

    Article • Biochemical Pharmacology, March 2012, Elsevier

    Dr Khosrow Kashfi

  61. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: A general property and evidence of a tissue type-independent effect

    Article • Biochemical Pharmacology, March 2012, Elsevier

    Dr Khosrow Kashfi

  62. Nitric Oxide Release Is Not Required to Decrease the Ulcerogenic Profile of Nonsteroidal Anti-inflammatory Drugs

    Article • Journal of Medicinal Chemistry, January 2012, American Chemical Society (ACS)

    Dr Khosrow Kashfi

  63. Cell Signaling & Molecular Targets in Cancer

    Article • January 2012, Springer Science + Business Media

    Dr Khosrow Kashfi

  64. Nitric Oxide−Releasing Hybrid Drugs Target Cellular Processes Through S-Nitrosylation

    Article • Forum on Immunopathological Diseases and Therapeutics, January 2012, Begell House

    Dr Khosrow Kashfi

  65. Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents

    Article • Bioorganic & Medicinal Chemistry Letters, December 2011, Elsevier

    Dr Khosrow Kashfi

  66. Abstract 807: Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr Khosrow Kashfi

  67. NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S-nitrosylation

    Article • Cancer Letters, December 2010, Elsevier

    Dr Khosrow Kashfi

  68. JS-K; a nitric oxide-releasing prodrug, modulates β-catenin/TCF signaling in leukemic Jurkat cells: Evidence of an S-nitrosylated mechanism

    Article • Biochemical Pharmacology, December 2010, Elsevier

    Dr Khosrow Kashfi

  69. Modulation of stress genes expression profile by nitric oxide-releasing aspirin in Jurkat T leukemia cells

    Article • Biochemical Pharmacology, June 2010, Elsevier

    Dr Khosrow Kashfi

  70. Abstract 1487: Nitric oxide-releasing NSAIDs suppress NF-κB signaling and increase caspase-3 enzyme activityin vitroandin vivothrough S-nitrosylation

    Article • April 2010, American Association for Cancer Research (AACR)

    Dr Khosrow Kashfi

  71. Abstract A42: Comparison between NO-ASA and NONO-ASA as safe anti-inflammatory, analgesic, antipyretic, antioxidant chemopreventive prodrugs

    Article • Cancer Prevention Research, January 2010, American Association for Cancer Research (AACR)

    Dr Khosrow Kashfi

  72. Abstract B86: JS‐K, a nitric oxide‐donating prodrug, modulates β‐catenin/TCF signaling in leukemic Jurkat cells through S‐nitrosylation

    Article • January 2010, American Association for Cancer Research (AACR)

    Dr Khosrow Kashfi

  73. Nitro-aspirin inhibits MCF-7 breast cancer cell growth: Effects on COX-2 expression and Wnt/β-catenin/TCF-4 signaling

    Article • Biochemical Pharmacology, November 2009, Elsevier

    Dr Khosrow Kashfi

  74. Anti-Inflammatory Agents as Cancer Therapeutics

    Article • January 2009, Elsevier

    Dr Khosrow Kashfi

  75. Abstract B109: Bioactivated chemotherapeutic agents based on ester-protected hydroxybenzyl phosphates (EHBP) for reversible alkylation of cellular nucleophiles

    Article • Cancer Prevention Research, November 2008, American Association for Cancer Research (AACR)

    Dr Khosrow Kashfi

  76. Abstract A23: Expression profile of genes altered by ester-protected hydroxybenzyl phosphates (EHBP) in T-leukemia cells

    Article • Cancer Prevention Research, November 2008, American Association for Cancer Research (AACR)

    Dr Khosrow Kashfi

  77. Abstract A64: Ester-protected hydroxybenzyl phosphates (EHBP) inhibit the growth of various cultured human cancer cells: Evidence of a tissue type-independent effect

    Article • November 2008, American Association for Cancer Research (AACR)

    Dr Khosrow Kashfi

  78. Abstract A35: JS-K, a nitric oxide-donating prodrug, inhibits the growth of leukemic jurkat cells and modulates β-catenin/TCF signaling

    Article • November 2008, American Association for Cancer Research (AACR)

    Dr Khosrow Kashfi

  79. The mechanism of action of nitric oxide-donating aspirin

    Article • Biochemical and Biophysical Research Communications, July 2007, Elsevier

    Dr Khosrow Kashfi

  80. NO-donating aspirin induces phase II enzymes in vitro and in vivo

    Article • Carcinogenesis, November 2005, Oxford University Press (OUP)

    Dr Khosrow Kashfi

  81. Non-COX-2 targets and cancer: Expanding the molecular target repertoire of chemoprevention

    Article • Biochemical Pharmacology, October 2005, Elsevier

    Dr Khosrow Kashfi

  82. NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells

    Article • Biochemical Pharmacology, October 2005, Elsevier

    Dr Khosrow Kashfi

  83. Is COX-2 a ‘collateral’ target in cancer prevention?

    Article • Biochemical Society Transactions, August 2005, Portland Press Ltd.

    Dr Khosrow Kashfi

  84. NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates β-catenin expression

    Article • Biochemical and Biophysical Research Communications, December 2004, Elsevier

    Dr Khosrow Kashfi

  85. Positional Isomerism Markedly Affects the Growth Inhibition of Colon Cancer Cells by Nitric Oxide-Donating Aspirin in Vitro and in Vivo

    Article • Journal of Pharmacology and Experimental Therapeutics, November 2004, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Khosrow Kashfi

  86. Nitric-oxide-donating NSAIDs as agents for cancer prevention

    Article • Trends in Molecular Medicine, July 2004, Elsevier

    Dr Khosrow Kashfi

  87. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property?

    Article • Biochemical Pharmacology, June 2004, Elsevier

    Dr Khosrow Kashfi

  88. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APCMin/+) mice

    Article • Biochemical and Biophysical Research Communications, January 2004, Elsevier

    Dr Khosrow Kashfi

  89. Nitric oxide-donating aspirin inhibits β-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear β-catenin–TCF association

    Article • Proceedings of the National Academy of Sciences, October 2003, Proceedings of the National Academy of Sciences

    Dr Khosrow Kashfi

  90. No-donating NSAIDs are more potent than traditional NSAIDs in inhibiting the growth of cultured human colon cancer cells

    Article • Gastroenterology, April 2003, Elsevier

    Dr Khosrow Kashfi

  91. Lipid Metabolism and Membrane Composition Are Altered in the Brains of Type II Diabetic Mice

    Article • Journal of Neurochemistry, November 2002, Wiley

    Dr Khosrow Kashfi

  92. Inhibition of Bacterial Superantigens by Peptides and Antibodies

    Article • Infection and Immunity, October 2002, ASM Journals

    Dr Khosrow Kashfi

  93. Colon cancer prevention with NO-releasing NSAIDs

    Article • Prostaglandins & Other Lipid Mediators, February 2002, Elsevier

    Dr Khosrow Kashfi

  94. The retinoid fenretinide inhibits proliferation and downregulates cyclooxygenase-2 gene expression in human colon adenocarcinoma cell lines

    Article • Cancer Letters, March 2001, Elsevier

    Dr Khosrow Kashfi

  95. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells

    Article • Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, May 1996, Elsevier

    Dr Khosrow Kashfi

  96. Comparative effects of omeprazole on xenobiotic metabolizing enzymes in the rat and human*

    Article • Clinical Pharmacology & Therapeutics, December 1995, Springer Science + Business Media

    Dr Khosrow Kashfi

  97. Omeprazole Coinduces Multiple Xenobiotic-metabolizing Enzymes in the Rata

    Article • Annals of the New York Academy of Sciences, September 1995, Wiley

    Dr Khosrow Kashfi

  98. Phenolic Antioxidants Induce UDP-glucuronosyltransferase in Rat Livera

    Article • Annals of the New York Academy of Sciences, September 1995, Wiley

    Dr Khosrow Kashfi

  99. Temperature effects on malonyl-CoA inhibition of carnitine palmitoyltransferase I

    Article • Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, July 1995, Elsevier

    Dr Khosrow Kashfi

  100. Diabetes and proteolysis: Effects on carnitine palmitoyltransferase-I and malonyl-CoA binding

    Article • Lipids, May 1995, Wiley

    Dr Khosrow Kashfi

  101. Differential induction of glutathione S-transferase in rat aorta versus liver

    Article • Biochemical Pharmacology, May 1994, Elsevier

    Dr Khosrow Kashfi

  102. Hepatic carnitine palmitoyltransferase-I has two independent inhibitory binding sites for regulation of fatty acid oxidation

    Article • Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, May 1994, Elsevier

    Dr Khosrow Kashfi

  103. Malonyl-CoA inhibits proteolysis of carnitine palmitoyltransferase

    Article • Biochemical and Biophysical Research Communications, July 1991, Elsevier

    Dr Khosrow Kashfi

  104. Effects of cholesterol loading of mouse macrophages on carnitine palmitoyltransferase activity and sensitivity to inhibition by malonyl-CoA

    Article • Biochemical and Biophysical Research Communications, June 1991, Elsevier

    Dr Khosrow Kashfi

  105. Inhibition of mitochondrial carnitine palmitoyltransferases by adriamycin and adriamycin analogues

    Article • Biochemical Pharmacology, October 1990, Elsevier

    Dr Khosrow Kashfi

  106. Topology of Hepatic Mitochondrial Carnitine Palmitoyltransferase I

    Article • Springer Science + Business Media

    Dr Khosrow Kashfi